180 Life Sciences (NASDAQ:ATNF) (NASDAQ: ATNF) is a clinical-stage biotechnology company dedicated to developing novel therapies in the fields of oncology, pain management and women’s health. The company’s lead programs include AT-01, a synthetic photosensitizer designed for targeted light-based therapy in prostate cancer; AT-02, a photobiomodulation treatment for refractory pain conditions such as diabetic neuropathy and cancer-related pain; and OBE022, an orally administered prostaglandin F2α receptor antagonist being explored to prevent and manage preterm labor.
Formed through a series of strategic mergers and investments, 180 Life Sciences strengthened its pipeline in late 2020 with the acquisition of Cantex Pharmaceuticals, thereby in-licensing OBE022 and expanding its focus into women’s health. Each of the company’s programs has advanced into Phase 2 trials, with clinical sites operating in the United States and Europe. These studies are designed to evaluate safety, tolerability and preliminary efficacy in patient populations where unmet medical needs remain high.
Based in New York, with research collaborations spanning North America and Europe, 180 Life Sciences leverages a combination of proprietary chemistry and phototherapy platforms to address complex disease processes. The company’s management team is led by Chairman and Chief Executive Officer Stephen G. Thomas, whose background includes senior roles in both public and private life sciences enterprises. Under this leadership, 180 Life Sciences seeks to build a diversified pipeline that can deliver innovative treatments across multiple therapeutic areas.
With its focus on clinical progression and regulatory milestones, 180 Life Sciences aims to position itself as a leader in specialty therapeutics. The company continues to engage with investigators, regulatory authorities and potential commercial partners to advance its product candidates toward approval and, ultimately, patient access.
